Examination of the Regulation of Galectin-3 Expression in Cancer

Ahmed, Hafiz; Bandyopadhyaya, Gargi

doi:10.1007/978-1-4939-1396-1_24

Cited by 5 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is not consistent with the results obtained by Lambropoulou et al where high expression of galectin 3 was independently associated with the infiltration depth and the histological grade of the tumor [ 25 ]. Both proliferative and apoptotic effects of galectin 3 are well illustrated by Hafiz et al who demonstrated that galectin 3 as expressed on the surface of cells is involved in homotypic cell adhesion via binding to soluble complementary glycoconjugates [ 26 , 27 ]. Interactions between metastatic neoplastic cells with vascular endothelium are critical in the early stages of tumor metastasis [ 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

Could Galectin 3 Be a Good Prognostic Factor in Endometrial Cancer?

et al. 2020

View full text Add to dashboard Cite

Galectin 3 is a modulator of several basic biological functions. It may be involved in the development of obesity and type 2 diabetes—risk factors of endometrial cancer. The study involved 144 patients, after abrasion due to postmenopausal bleeding. Galectin 3 concentrations were quantified in serum by multiplex fluorescent bead-based immunoassays. Median serum galectin 3 concentrations revealed significant differences between FIGO III and IV vs. FIGO I and II patients. Statistically higher concentrations were reported for patients with lymph node metastases compared to patients without it (p = 0.001) as well as in patients with lymphovascular space invasion compared to patients without LVSI (p = 0.02). No statistically significant differences were observed for median of galectin 3 levels depending on the surgical procedure (laparoscopy vs. laparotomy, p = 0.0608). Patients with galectin 3 levels exceeding the median value were characterized by overall survival being shorter by 11.9 months. High levels of galectin 3 were correlated with shorter disease-free survival, the difference is up to 14.8 months. Galectin 3 can be an independent prognostic factor in patients with endometrial cancer. Among the recognized prognostic factors and the concentrations of the galectin 3 marker at the adopted time points, the univariate analysis showed a significant effect of staging, grading, and cutoff galectin 3 on the OS. For multivariate analysis, the galectin 3 cutoff point had the greatest significant impact on OS.

show abstract

Section: Discussionmentioning

confidence: 99%

Could Galectin 3 Be a Good Prognostic Factor in Endometrial Cancer?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…3 – 6 Galectin-3 has several functions because it is expressed in different locations and can attach to a variety of ligands. 3 , 4 , 7 – 9 It also takes part in the transformation process and carcinogenesis. Several studies have shown that galectin-3 plays significant roles in a collection of neoplasm-associated biological activities including apoptosis, differentiation, adhesion, proliferation, migration, angiogenesis, invasion, and metastasis.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Several studies have shown that galectin-3 plays significant roles in a collection of neoplasm-associated biological activities including apoptosis, differentiation, adhesion, proliferation, migration, angiogenesis, invasion, and metastasis. [5][6][7][8][9][10][11] Previous studies have reported galectin-3 expression in several neoplasms and have attempted to estimate its diagnostic utility as a predictive factor for malignant progression. However, there remains a significant debate because galectin-3 has been found to be both over-and under-expressed in cancerous tissues compared with non-malignant tissues.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical significance of galectin-3 expression in urinary bladder carcinoma

Al‐Maghrabi

Khabaz

2023

J Int Med Res

View full text Add to dashboard Cite

Objective To uncover the clinical significance of galectin-3 in the evolution of urinary bladder cancer by defining galectin-3 expression and examining the relationship between its expression in a group of urothelial carcinomas versus normal tissues along with clinicopathological factors. Methods This retrospective study included histopathological reports and archival blocks and slides of all patients with urinary bladder cancer treated at King Abdulaziz University Hospital (Jeddah, Saudi Arabia). An anti-galectin-3 monoclonal antibody was used for immunohistochemical staining of tissue microarray slides comprising 128 cases of urothelium carcinoma and 24 specimens of normal bladder mucosa. Results Galectin-3 was downregulated during transformation, with positive expression found in 50 (39%) urinary bladder neoplasms, of which 33 (66%) showed weak immunostaining. All positively-stained malignant tumor and normal bladder mucosa samples showed cytoplasmic staining; a few samples also showed nuclear staining. No correlation was noted between galectin-3 and histotype, grade, stage, muscularis propria invasion, lymph node invasion, vascular invasion, or metastasis. A Cox proportional hazards model and Kaplan–Meier survival curves did not show differences in survival on the basis of galectin-3 expression. Conclusion Galectin-3 is down-regulated in bladder cancer but is not a helpful marker for the diagnosis or prognosis of urinary bladder cancer.

show abstract

“…Galectin-12 was shown to be silenced by DNA methylation in colorectal cancer (CRC) cell lines and primary samples (Xue et al, 2016;Katzenmaier et al, 2017). Moreover, previous studies showed that LGALS3 promoter CpG islands were heavily methylated in the early stages of prostate adenocarcinoma (Ahmed and Bandyopadhyaya, 2015). Interestingly, another study reported that the average methylation degree of five CpG sites in the LGALS3 gene regulatory region was significantly decreased in thyroid cancer tissues (Keller et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Promoter methylation might shift the balance of Galectin-3 & 12 expression in de novo adult acute myeloid leukemia patients

Assem

El-Araby²,

Al‐Karmalawy³

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) was reported as the most common type of leukemia among adults. Galectins constitute a family of galactose-binding proteins reported to play a critical role in many malignancies including AML. Galectin-3 and -12 are members of the mammalian galectin family. To understand the contribution of galectin-3 and -12 promoter methylation to their expression, we performed bisulfite methylation-specific (MSP)-PCR and bisulfite genomic sequencing (BGS) of primary leukemic cells in patients with de novo AML before receiving any therapy. Here, we show a significant loss of LGALS12 gene expression in association with promoter methylation. The lowest degree of expression was found in the methylated (M) group while the highest degree was in the unmethylated (U) group and the partially methylated (P) group expression lies in between. This was not the case with galectin-3 in our cohort unless the CpG sites analyzed were outside the frame of the studied fragment. We were also able to identify four CpG sites (CpG number 1, 5, 7& 8) in the promoter region of galectin-12; these sites must be unmethylated so that expression can be induced. As far as the authors know, these findings were not previously concluded in earlier studies.

show abstract

Examination of the Regulation of Galectin-3 Expression in Cancer

Cited by 5 publications

References 39 publications

Could Galectin 3 Be a Good Prognostic Factor in Endometrial Cancer?

Could Galectin 3 Be a Good Prognostic Factor in Endometrial Cancer?

Clinical significance of galectin-3 expression in urinary bladder carcinoma

Promoter methylation might shift the balance of Galectin-3 & 12 expression in de novo adult acute myeloid leukemia patients

Contact Info

Product

Resources

About